- Company
- Drug-resistant TB drug Dovprela applies for reimbursement
- by Eo, Yun-Ho Mar 16, 2022 05:57am
- ‘Dovprela,’ the first new drug introduced in the field of tuberculosis in 50 years, is attempting reimbursement listing in Korea. According to industry sources, Viatris Korea has submitted an application for the reimbursement listing of its multi-drug resistant tuberculosis treatment, Dovprela (pretomanid). Dovprela, which was first
- Company
- Whether companies give up developing COVID-19 vaccines
- by Kim, Jin-Gu Mar 16, 2022 05:57am
- Domestic pharmaceutical companies are divided over the development of the COVID-19 vaccine. After the introduction of Pfizer, Moderna Vaccine, some companies stopped developing due to reduced commerciality and difficulties in recruiting clinical participants. Companies that are newly developing in preparation of the coronavirus are steadily
- Company
- Exon 20 insertion targeting Exkivity comes to Korea
- by Eo, Yun-Ho Mar 15, 2022 05:58am
- Takeda’s new lung cancer drug ‘Exkivity’ is coming to Korea. According to industry sources, Takeda Pharmaceuticals Korea recently submitted an application for the marketing authorization of ‘Exkivity (mobocertinib).’ The drug is expected to be approved within the year at the earliest. Exkivity was approved in the US in September
- Company
- Samsung·Celltrion speeds up dev of follow-on similars
- by Ji Yong Jun Mar 15, 2022 05:58am
- Celltrion and Samsung Bioepis’s follow-on biosimilars are gaining momentum in the global market. A total of 11 biosimilars from the two companies are being prepared for their launch into the global market. According to the industry on the 14th, Celltrion’s Avastin biosimilar is awaiting approval in the US and European market this year.
- Company
- Pharma·Biopharmas make or break COVID-19 CMO deals
- by Ji Yong Jun Mar 14, 2022 05:51am
- Domestic pharmaceutical companies are experiencing mixed results regarding their CMO businesses for COVID-19 vaccines. Samsung Biologics and SK Bioscience are already in the process of manufacturing COVID-19 vaccines. On the other hand, GC Pharma and Huons Global gave up their COVID-19 vaccine CMO business. In addition, uncertainties continu
- Company
- Roche,set to establish a Korean precision medical ecosystem
- by jung, sae-im Mar 13, 2022 08:01pm
- Roche Korea announced on the 7th that it has signed term sheet with the KSMO to form a partnership with four organizations, including the KCSG, NCC, and the KHIDI, to establish a Korean precision medical ecosystem. Turnsheet is the process of specifying and agreeing on major contract conditions such as goals, scope of cooperation, roles and r
- Company
- Dong-A ST submitted an appeal against patent dispute
- by Kim, Jin-Gu Mar 13, 2022 07:59pm
- The battle over material patent of Forxiga (Dapagliflozin Propanediol Hydrate), an SGLT-2 inhibitor-based diabetes treatment, will head to the third round. The opportunity for Dong-A ST's generic for Forxiga to release is also expected to vary depending on when and how the Supreme Court decides. ◆ Dong-A ST, a letter of appeal was subm
- Company
- Sales of oral contraceptives rebound…4th gen Yaz sales up 2
- by Ji Yong Jun Mar 11, 2022 06:04am
- The oral contraceptive market grew greatly last year. Sales of the fourth-generation contraceptive Bayer Korea’s Yaz increased greatly, and the return of the third-generation Dong-A Pharmaceutical’s Mybora and the release of GC Pharm’s Dearmesoon had also contributed to market expansion. According to the market research institution IQVIA
- Company
- Global lead Humira’s sales drop... biosimilars occupy 16%
- by Chon, Seung-Hyun Mar 11, 2022 06:04am
- The &8361;200 billion autoimmune disease market has finally revealed its form in Korea. The growth of the global leading product ‘Humira’ had fallen somewhat due to the introduction of its biosimilars. The 5 biosimilars by domestic companies Celltrion, Samsung Bioepis, LG Chem, etc. are also increasing their influence in the market, but their
- Company
- MSD’s 15-valent vaccine ‘Vaxneuvance’ comes to Korea
- by Eo, Yun-Ho Mar 10, 2022 05:54am
- MSD aims to challenge the dominance of ‘Prevenar 13’ in the domestic pneumococcal vaccine market. According to industry sources, MSD Korea has submitted an application and is being reviewed for the marketing authorization of its 15-valent pneumococcal vaccine ‘Vaxneuvance,' and may be approved within the year. If released, Vaxneuv
